Research programme: secondary hyperparathyroidism therapy - LEO PharmaAlternative Names: KH 1722; Secondary hyperparathyroidism therapy research programme - LEO Pharma
Latest Information Update: 26 Mar 2010
At a glance
- Originator LEO Pharma
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hyperparathyroidism
Most Recent Events
- 26 Oct 2004 Preclinical trials in Hyperparathyroidism in Denmark (unspecified route)